pufa 22:6 c

PUFA 22:6 c refers to docosahexaenoic acid (DHA), a 22‑carbon, six‑double‑bond long‑chain omega‑3 polyunsaturated fatty acid (PUFA). Fatty acids are classified by chain length and number of double bonds; DHA’s designation "22:6" reflects this structure, and the "n‑3" or omega‑3 classification indicates the first double bond is three carbons from the methyl end. PUFAs like DHA are distinct from saturated and monounsaturated fatty acids in that they contain multiple cis double bonds, which give them flexibility and functional roles in cell membranes that saturated fats lack. DHA is found in high concentrations in the central nervous system, particularly in retinal and cerebral membranes, where it influences membrane fluidity, receptor function, and signal transduction. Unlike alpha‑linolenic acid (ALA), a shorter chain omega‑3, humans have limited ability to convert ALA into DHA, making dietary intake essential for maintaining tissues rich in DHA, such as the brain and eyes. Although the Institute of Medicine/National Academy of Medicine (IOM/NAM) and NIH have not set a separate Recommended Dietary Allowance (RDA) for DHA alone, guidelines often combine DHA with eicosapentaenoic acid (EPA) when setting intake recommendations. DHA originates from marine microalgae at the base of the ocean food chain and accumulates in fish and seafood, which are the primary dietary sources. The structural presence of DHA in cell membranes affects membrane microdomains, influences neurotransmitter receptor function, and plays roles in synaptogenesis and neuroplasticity. It also participates in the generation of specialized pro‑resolving lipid mediators that help counteract chronic inflammation, a central feature of many modern chronic diseases. Because of its importance in early development, DHA is often added to infant formulas to approximate human milk composition. Without adequate dietary intake, DHA concentrations in phospholipids fall, potentially impacting neural and visual development, especially in infancy and pregnancy.

Docosahexaenoic acid (DHA) is integral to numerous physiological processes, reflecting its role as a structural lipid and signaling molecule. DHA is a major component of the phospholipid bilayer in neural and retinal cells; its unique conformation influences membrane fluidity and receptor function, facilitating optimal neurotransmission and visual signal transduction. In cardiovascular health, DHA helps modulate lipid profiles and eicosanoid synthesis, skewing signaling toward less pro‑inflammatory pathways and supporting vascular function. Long‑term epidemiological and clinical research has associated higher intakes of DHA and EPA with reduced triglycerides, modest reductions in coronary heart disease risk, and potential anti‑arrhythmic effects. Many expert bodies, including international nutrition panels, recommend at least ~250 mg/day of combined EPA and DHA for cardiovascular risk reduction, even in the absence of specific U.S. DRIs. DHA also contributes to brain development during pregnancy and infancy; observational studies find that higher maternal DHA status correlates with longer gestation, reduced risk of early preterm delivery, and potentially improved neurodevelopmental outcomes, though randomized trial data vary. In older adults, DHA may support cognitive function and neural integrity, with some research suggesting diets rich in DHA are linked to reduced cognitive decline. The capacity of DHA to serve as a precursor to specialized pro‑resolving mediators such as resolvins and protectins underlies its role in inflammation resolution, beyond simple anti‑inflammatory actions. While evidence for DHA’s impact spans cardiovascular, cognitive, and developmental health, the strength of evidence varies by outcome. For example, large trials indicate consistent triglyceride reductions, while effects on stroke or dementia prevention remain less definitive. Mechanistic research continues to elucidate how DHA influences gene expression, membrane signaling, and lipid mediator networks to yield broad systemic effects. Because humans inefficiently convert plant ALA to DHA, incorporating preformed DHA from marine sources is critical for achieving physiologically meaningful tissue levels and associated health benefits.

Despite the recognized importance of DHA, U.S. federal dietary guidance has not established a discrete RDA for DHA alone. The NIH Office of Dietary Supplements notes that Adequate Intakes (AI) exist for total omega‑3 fatty acids in infancy and for ALA in older ages, but not specifically for EPA or DHA. Therefore, many national and international expert groups provide intake targets for combined EPA and DHA, frequently recommending around 250 mg per day for healthy adults to support cardiovascular health and overall omega‑3 status. In pregnancy and lactation, an additional DHA intake of 100‑200 mg/day beyond baseline EPA+DHA targets is often advised to support fetal brain and retinal development and to maintain maternal status. Intake recommendations vary globally; some guidelines emphasize at least two servings of fatty fish per week (~250‑500 mg EPA+DHA daily equivalent). These recommendations reflect associations with improved lipid profiles, reduced inflammation markers, and support of neural development. Certain clinical organizations further adjust targets for specific health conditions; for instance, higher intakes may be used in hypertriglyceridemia management under medical supervision. Intake needs also differ across life stages: infants receive DHA through breast milk or fortified formula, while older adults may require more intentional dietary sources owing to decreased endogenous synthesis. Because ALA conversion to DHA is inefficient, relying solely on plant‑based omega‑3 sources often fails to achieve adequate DHA status, particularly for tissues with high DHA demand. Understanding personal dietary patterns and tailoring intake to life stage, health status, and dietary preferences is central to meeting DHA needs.

Clinical deficiency of DHA alone is uncommon in populations consuming regular dietary sources of long‑chain omega‑3s, but suboptimal intake and low tissue levels are prevalent. A deficiency or insufficiency in DHA can be inferred from low blood phospholipid or erythrocyte membrane EPA+DHA percentages, though specific reference ranges lack formal consensus. Suboptimal DHA status may contribute to signs related to neural and visual function; in infancy, inadequate DHA has been linked to delayed visual acuity development, as retinal membranes depend heavily on DHA. In pregnancy, low maternal DHA levels are associated with shorter gestation and increased risk of preterm birth. In adults, low DHA status may correlate with mood disturbances or cognitive decline, though causality is complex and multifactorial. Beyond developmental outcomes, low DHA levels often coincide with elevated triglycerides and inflammatory markers, potentially exacerbating cardiometabolic risk. Because DHA plays a role in eicosanoid balance and inflammation resolution, insufficient intake may blunt these regulatory systems. Symptoms of very low omega‑3 status generally include dry skin, impaired concentration, and mood fluctuations, but these are nonspecific and overlap with other nutritional and health conditions. Populations at risk for low DHA intake include those consuming little to no seafood or marine oils, individuals with limited access to DHA‑rich foods, and those with increased physiological needs such as pregnant and lactating women. Assessment of DHA status typically involves measuring plasma or erythrocyte phospholipid fatty acids as percentages of total fatty acids, with higher percentages reflecting better omega‑3 status. However, no universally accepted optimal blood range exists, and values vary by lab methodology. Regardless, ensuring adequate DHA intake through diet or supplementation is a proactive strategy to prevent recognized functional deficits associated with low long‑chain omega‑3 levels.

Docosahexaenoic acid is concentrated in marine sources, particularly fatty fish and seafood. According to USDA nutrient composition data, cooked Atlantic salmon, sardines, mackerel, and tuna provide substantial amounts of DHA per serving, often exceeding 1 g/serving of combined EPA and DHA in oily fish. Other seafood such as oysters, mussels, and fish roe also contribute meaningful DHA levels, though amounts vary. Marine oils such as fish oil and cod liver oil are among the richest sources, delivering concentrated doses of DHA and EPA per teaspoon or softgel. In contrast, plant‑based foods contain primarily ALA, which humans inefficiently convert to DHA; examples include flaxseed, chia seeds, walnuts, and hemp seeds. Specialty eggs and dairy products from animals fed omega‑3‑rich diets offer modest DHA increases compared with conventional products. Regular consumption of fatty fish at least twice weekly aligns with many intake recommendations, maximizing DHA intake while also providing other nutrients such as vitamin D and selenium. For individuals who avoid seafood, algal oil supplements provide preformed DHA in a vegan‑appropriate form derived directly from microalgae, the primary producers of marine omega‑3 fatty acids. While fish and seafood are the most potent dietary sources of DHA, a diverse dietary pattern that incorporates both marine and fortified foods can support overall omega‑3 status. Practical culinary strategies include grilling salmon, adding sardines to salads, enjoying oysters on the half shell, and using fish oil or algal oil supplements when food sources are insufficient to meet recommended intake targets.

DHA is absorbed in the small intestine after dietary fats are emulsified by bile salts. The efficiency of absorption for long‑chain PUFAs like DHA is high, similar to other dietary fats, often exceeding 90% when consumed with a meal containing fat. Absorbed DHA incorporates into chylomicrons and enters the lymphatic system, ultimately distributing to tissues including the brain, eyes, and heart. Co‑consuming DHA with other fats can enhance micelle formation, facilitating uptake. Factors that may inhibit absorption include malabsorption syndromes and conditions that reduce bile production or pancreatic enzyme activity. Bioavailability varies slightly by food form; DHA from fish and algal oil appears similarly bioavailable, while esterified and triglyceride forms in supplements may differ marginally in uptake efficiency. Because DHA integrates into cell membranes, sustained intake influences membrane composition over weeks to months.

Supplementation with DHA is common, particularly for individuals with low seafood intake, pregnancy, or specific health goals such as lowering triglycerides. Algal oil offers a plant‑based preformed DHA option, while fish oil provides DHA with EPA. Evidence indicates that supplementation can raise blood and tissue EPA+DHA levels and may confer benefits in cardiovascular risk reduction, neural development, and inflammatory modulation. Typical supplemental doses range from 250 mg to several grams of combined EPA+DHA, depending on health status and clinician recommendations.

While DHA from food sources presents little toxicity risk, high supplemental intakes may increase bleeding risk, particularly when combined with anticoagulants. Some regulatory guidance cautions against supplemental EPA+DHA above 2 g/day without medical oversight, though formal tolerable upper intake levels are not established by NIH.

DHA and omega‑3 supplements can interact with anticoagulant and antiplatelet medications, potentially enhancing bleeding risk. Individuals on warfarin, direct oral anticoagulants, or high‑dose aspirin should consult clinicians about omega‑3 supplement use.

Common Forms: Fish oil capsules, Algal oil DHA supplements

Typical Doses: 250–1000+ mg combined EPA+DHA daily

When to Take: With meals containing fat to enhance absorption

Best Form: Triglyceride/emulsified forms of DHA/EPA

⚠️ Interactions: Anticoagulants, Antiplatelet drugs